BD Locks FDA Emergency Use Nod For At-Home COVID-19 Antigen Test

The FDA has issued an Emergency Use Authorization (EUA) for Becton Dickinson and Co's (NYSE:BDX) BD Veritor At-Home COVID-19 Test.
Also Read: BD's Automated Molecular Diagnostics Platform Wins FDA Approval, Initial Test For HPV
The at-home COVID-19 rapid antigen test uses computer vision technology in a smartphone to interpret and provide a digital display of testing results.
It does not require a prescription, a laboratory, or a long wait for results.
The test will initially be made available to businesses, schools, and governments looking to provide a self-testing option for employees or students.
The BD Veritor At-Home COVID-19 Test will use a simple, pain-free nasal swab and an easy-to-use mobile app from Scanwell Health that yields reliable test results in 15 minutes.
The app is available on iOS and Android. The test can also be used for children as young as two years old with samples collected by an adult.
Related content: Benzinga's Full FDA Calendar
Price Action: BDX shares closed 0.35% lower at $247 on Wednesday.